Tyra Biosciences

Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.

Tyra has built a nimble and experienced team to rapidly translate new discoveries into the clinic with a singular focus on acquired resistance in oncology.

Tyra Biosciences was founded in 2018 by Todd Harris alongside with Daniel C Bensen. The company is headquartered in Carlsbad, California.

 

Tyra Biosciences is combining insights from structure-based drug design (SBDD), kinase biology, computational chemistry and smart clinical development to discover and develop next-gen small molecule therapies that are active against both wild type and mutant targets.

 

Tyra Biosciences has raised $50M in a Series A financing on Jan 10, 2020. The financing round was co-led by Alta Partners, RA Capital Management, Boxer Capital of Tavistock Group, and Canaan.

 

 

  • Year founded: 2018
  • Funding Info: $50M over 1 Round (Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 2-10
  • Business Valuation: NA
  • City/Town: Carlsbad
  • State: California
  • Country: United States
Related businesses